A prospective, randomized trial of gonadotropin-releasing hormone agonist plus estrogen-progestin or progestin" add-back" regimens for women with leiomyomata …
AJ Friedman, M Daly… - The Journal of …, 1993 - academic.oup.com
Abstract Treatment of women with myomas with GnRH agonists (GnRH-a) for 3-6 months
will result in profound hypoestrogenism, a significant but temporary reduction in uterine …
will result in profound hypoestrogenism, a significant but temporary reduction in uterine …
Steroid hormones and leiomyomas
Uterine leiomyomas or fibroids are benign, hormonally responsive, smooth muscle tumors
that have been reported to affect 20% to 40% of premenopausal women making them the …
that have been reported to affect 20% to 40% of premenopausal women making them the …
A placebo-controlled trial of a depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata
WD Schlaff, EA Zerhouni, JAM Huth, J Chen… - Obstetrics & …, 1989 - journals.lww.com
Several studies have shown that treatment with a gonadotropin-releasing hormone (GnRH)
analogue can reduce uterine volume in women with leiomyomata. However, no study to …
analogue can reduce uterine volume in women with leiomyomata. However, no study to …
A clinical control study on the treatment of uterine leiomyoma with gonadotrophin releasing hormone agonist or mifepristone
C Zeng, M Gu, H Huang - Zhonghua fu chan ke za zhi, 1998 - europepmc.org
Objective To compare the results and side effects in treating uterine leiomyoma with
gonadotrophin releasing hormone agonist (GnRH-a) or mifepristone. Methods 75 patients …
gonadotrophin releasing hormone agonist (GnRH-a) or mifepristone. Methods 75 patients …
Options for medical treatment of myomas
BW Rackow, A Arici - Obstetrics and Gynecology Clinics, 2006 - obgyn.theclinics.com
Uterine myomas are the most common benign tumor in women of reproductive age, and
affect 20% to 50% of this population. The prevalence of these tumors increases with age [1 …
affect 20% to 50% of this population. The prevalence of these tumors increases with age [1 …
Leiomyosarcomas: clinical presentation
LB Schwartz, MP Diamond, PE Schwartz - American journal of obstetrics …, 1993 - Elsevier
Objective: The ability to preoperatively distinguish benign from malignant myomas is
increasingly important because of the availability of more conservative approaches to …
increasingly important because of the availability of more conservative approaches to …